Compounds > hedione
Page last updated: 2024-12-07

hedione

Hedione, also known as methyl dihydrojasmonate, is a synthetic fragrance compound with a floral, fruity, and green odor reminiscent of jasmine. It is widely used in perfumes and cosmetics, particularly in floral, fruity, and aldehydic fragrances. Its synthesis involves several steps, typically starting with the reaction of a cyclopentanone derivative with a Grignard reagent. Hedione has been found to exhibit various biological effects, including anti-inflammatory and antioxidant properties. It is studied for its potential applications in pharmaceuticals and cosmetics. Hedione's unique olfactory profile and its versatility in fragrance formulations make it a highly valued and extensively researched compound.'

Cross-References

ID SourceID
PubMed CID102861
CHEMBL ID1530328
CHEBI ID195265
SCHEMBL ID113649
MeSH IDM000614351

Synonyms (82)

Synonym
EU-0083698
MLS002696002
smr000387079
SDCCGMLS-0066789.P001
einecs 246-495-9
kharismal
fema no. 3408
methyl 3-oxo-2-pentylcyclopentaneacetate
methyl (2-pentyl-3-oxocyclopentyl)acetate
methyl dihydrojasmonate
hedione
SPECTRUM4_001758
SPECTRUM_001583
SPECTRUM5_000616
BSPBIO_003524
UNM000000712401
NCGC00095846-01
D1431
KBIO2_007199
KBIOGR_002236
KBIO2_002063
KBIO3_002748
KBIO2_004631
KBIOSS_002063
SPECTRUM2_000558
SPECTRUM3_001924
SPBIO_000635
SPECTRUM1504910
24851-98-7
methyl (3-oxo-2-pentylcyclopentyl)acetate
cyclopentaneacetic acid, 3-oxo-2-pentyl-, methyl ester
NCGC00095846-02
STK072613
HMS1617K17
methyl 3-oxo-2-pentyl-1-cyclopentaneacetate
2-amylcyclopentan-1-one-3-acetic acid methyl ester
methyl 2-(3-oxo-2-pentylcyclopentyl)acetate
CHEBI:195265
AKOS001683947
NCGC00095846-03
cas-24851-98-7
dtxcid109325
tox21_303588
dtxsid2029325 ,
NCGC00257324-01
tox21_202172
NCGC00259721-01
CHEMBL1530328
dihydrojasmonic acid, methyl ester
BBL009815
unii-3gw44cie3y
3gw44cie3y ,
methyl 3-oxo-2-pentyl-cyclopentaneacetate
ec 246-495-9
CCG-38726
FT-0624961
FT-0624962
S5139
methyl dihydrojasmonate [fhfi]
methyldihydrojasmonate [inci]
dihydrojasmonic acid methyl
FD7202
methyl dihydrojasmonate [mi]
MDJ ,
methyl dihydrojasmonate (synthetic)
2-(3-oxo-2-(pentan-1-yl)cyclopentyl)acetic acid methyl ester
SCHEMBL113649
methyl 3-oxo-2-pentylcyclopentylacetate
methyl 2-pentyl-3-oxo-cyclopentylacetate
3-oxo-2-pentyl-cyclopentane-acetic acid methyl ester
W-107278
methyl?dihydrojasmonate
sr-05000002474
SR-05000002474-1
jessamona
128087-96-7
DS-6422
methyl2-(3-oxo-2-pentylcyclopentyl)acetate
AMY15376
CS-W014206
HY-N7084
methyl dihydrojasmonate (cis- and trans- mixture)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (8 Product(s))

Product Categories

Product CategoryProducts
Household Essentials3
Beauty & Personal Care5

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Attitude Fabric Softener 80 Loads - Wildflowers -- 67.6 fl ozAttitudeHousehold Essentialsfloral, glycerin, methyldihydrojasmonate, caprylyl glucoside2024-11-29 10:47:42
Attitude Liquid Laundry Detergent 4X Concentrated HE Wildflowers -- 135.3 oz - 160 LoadsAttitudeHousehold Essentialsfloral, sodium gluconate, glycerin, methyldihydrojasmonate, sodium citrate2024-11-29 10:47:42
Attitude Liquid Laundry Detergent 4X Concentrated HE Wildflowers -- 67.6 fl oz - 80 LoadsAttitudeHousehold Essentialsfloral, sodium gluconate, glycerin, methyldihydrojasmonate, sodium citrate2024-11-29 10:47:42
Attitude Super Leaves Conditioner - Moisture Rich -- 8 fl ozAttitudeBeauty & Personal CareCitric acid, Cetearyl alcohol, Citric acid, Pentadecalactone, Glyceryl stearate, Methyl dihydrojasmonate, Hexyl salicylate, Maltodextrin, Sodium benzoate2024-11-29 10:47:42
Attitude Super Leaves Shampoo - Clarifying -- 16 fl ozAttitudeBeauty & Personal CareGlyceryl oleate, Citric acid, Citric acid, Panthenol, Methyl dihydrojasmonate, Maltodextrin, Sodium benzoate2024-11-29 10:47:42
Attitude Super Leaves Shampoo - Moisture Rich -- 16 fl ozAttitudeBeauty & Personal CareGlyceryl oleate, Citric acid, Citric acid, Panthenol, Pentadecalactone, Methyl dihydrojasmonate, Hexyl salicylate, Maltodextrin, Sodium benzoate2024-11-29 10:47:42
Common Ground Natural Body Wash With Avocado -- 16.9 fl ozCommon GroundBeauty & Personal Carecitric acid, citric acid, cocamidopropyl betaine, diethyl phthalate, galaxolide, glycerine, methyl dihydrojasmonate, sodium benzoate, sodium lauryl ether sulfate2024-11-29 10:47:42
Common Ground Natural Hand & Body Lotion with Avocado -- 8.4 fl ozCommon GroundBeauty & Personal Carecitric acid, cetearyl alcohol, citric acid, galaxolide, glycerine, methyl dihydrojasmonate, palmitic acid, palmitic acid, sodium benzoate, stearic acid2024-11-29 10:47:42

Drug Classes (1)

ClassDescription
lipid'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.89270.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency30.63790.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.83740.003041.611522,387.1992AID1159552
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.05490.001024.504861.6448AID743215
thyroid stimulating hormone receptorHomo sapiens (human)Potency48.06430.001628.015177.1139AID1224843
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency71.91560.000627.21521,122.0200AID743219
TAR DNA-binding protein 43Homo sapiens (human)Potency2.81841.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's8 (66.67)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.63 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index109.88 (26.88)
Search Engine Supply Index2.75 (0.95)

This Compound (52.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
chemdatabank.com